Policies related to drug approval for treatment of rare diseases. Regulatory flexibilities afforded to neurodegenerative diseases as provided for in the Act of ALS.
Government entities lobbied:Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE
pac.dog is a free, independent, non-partisan research tool. Every candidate, committee, bill, vote, member, and nonprofit on this site is mirrored from primary U.S. government sources (FEC, congress.gov, govinfo.gov, IRS) and each state's Secretary of State / election commission — no third-party data vendors, no paywall, no editorial intermediation. Citations to the originating source are on every detail page.